

Notice of Extraordinary General Meeting of Genovis AB

The shareholders of Genovis AB (publ) are hereby invited to an Extraordinary General Meeting on Friday, December 20, 2019 in Genovis premises at Scheeletorget 1 (The Spark) Medicon Village, Lund.

12.00 – 12.20 pm Registration

12.30 pm General Meeting convened

Right to participate. Registration

Shareholders who are registered in the register of shareholders maintained by Euroclear Sweden AB on December 13, 2019 and who have notified the company of their intention to attend the Annual General Meeting by no later than December 16, 2019, preferably before 3:00 p.m., have the right to attend the Annual General Meeting. Notification may be made by mail at Genovis AB (publ), Box 790, S-220 07 Lund, Sweden, by phone +46 (0)46-10 12 30 or by email: info@genovis.com. Upon notification, shareholders must provide their name/company name, personal identity number/corporate identity number, address and phone number. Information about the number of assistants (maximum two) that the shareholder intends to bring to the meeting should also be included.

Shareholders who are represented by proxy shall issue a written, signed and dated power of attorney for the proxy. Shareholders should submit the power of attorney together with the notification of their intention to participate at the AGM. The expiry date of the proxy document may be no more than five years from its issue. Proxy forms are available on the company's website, www.genovis.com. Representatives of legal entities must present a copy of the certificate of registration or equivalent authorization documents showing the authorized signatory.

Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to attend the meeting, request that their nominee re-register their shares in their own name, so that the shareholder is registered in the shareholder register on December 13, 2019. Such registration may be temporary.

Proposed Agenda

1. Opening of the Meeting.
2. Election of Chairman of the Meeting.
3. Preparation and approval of voting list.
4. Approval of the agenda.
5. Election of one or two persons to verify the minutes.
6. Determination of whether the Meeting was duly convened
7. Dismissal and election of director and chairperson of the Board.
8. Meeting adjourned.

Item 7 Dismissal and election of director and chairperson of the Board

The company's principal owner proposes the dismissal of Mårten Winge, who is resigning from the Board of Directors at his own request. Sarah Fredriksson has been proposed to replace Mårten Winge. The company's principal owner propose that Sarah Fredriksson be elected to chair the Board.

Sarah Fredriksson in brief

Sarah Fredriksson, MSc, PhD; born 1968

Sarah is the CEO of Aqilion AB, a Swedish life science company that starts, develops and sells pharmaceutical projects at an early phase in the drug discovery process. In addition, she is a member of the board of directors of Sweden Bio, Respiratorius AB and LU Holding AB, as well as chairperson of the board of Edvince AB.

Sarah Fredriksson is the founder of Genovis and served as CEO of the company until 2015, after which she was chairperson of the board until 2016. In 2016 she was a finalist for the EU Prize for Women Innovators for her work at Genovis.

Lund, December 2019

Genovis AB (publ.)

Board of Directors